NCT06712082

A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants

A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics Following Intravenous Dose of PF-07264660 in Chinese Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to learn if the study medicine (called PF-07264660) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who: * are between 18 to 65 years of age. * are Chinese participants who are overtly healthy as determined by medical evaluation. * have a BMI (body mass index) of 19 to 28 kilogram per meter squared; and a total body weight of more than50 kilograms (110 pounds). All participants in this study will receive study medicine. Three-fourths will receive PF-07264660 and one-fourth will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The study medicine will be given as an IV infusion (directly into a vein) at the study clinic only one time. The study will compare the experiences of people receiving PF-07264660 to those of people who do not. This will help see if PF-07264660 is safe and how it behaves inside the human body. Participants will take part in this study for up to 181 days. During this time, the participants will stay at the study clinic for 5 days. After the stay, the participants will have 8 study visits at the study clinic.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PF-07264660	PF-07264660 solution for injection (single use only)
OTHER	Placebo	Placebo solution for injection (single use only)

Timeline

• Start date: 2025-02-24
• Primary completion: 2025-09-04
• Completion: 2025-09-04
• First posted: 2024-12-02
• Last updated: 2025-09-25

Locations

2 sites across 1 country: China

Regulatory

• FDA-regulated drug study